Imidazoquinoline Compounds Inducing Interferon-Alpha Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for allergic diseases, such as allergic rhinitis and asthma, and infectious diseases lack effective immunomodulatory strategies that can specifically induce human interferon-alpha while minimizing side effects and optimizing therapeutic profiles.
Innovation Solution
Development of novel compounds, specifically those of formula (I) and their salts, which act as potent inducers of human interferon-alpha with selectivity for IFNα over TNFα, potentially rebalancing the immune response and offering therapeutic benefits for allergic diseases, infectious diseases, and cancer, as well as serving as vaccine adjuvants.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for allergic diseases and infectious diseases, then current therapeutic options are available, but effective immunomodulatory strategies that specifically induce human interferon-alpha are lacking
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of imidazoquinoline compounds (formula I) to optimize their ability to induce interferon-alpha. Specific parameters including R1 (n-C3-6 alkyl), R2 (hydrogen or methyl), R3 (hydrogen or C1-6 alkyl), and m (integer 0-3) are systematically varied to enhance immunomodulatory activity while maintaining selectivity for IFNα over TNFα pathways.
2Reliability
If TLR7 agonists are administered to induce interferon, then immune response is stimulated, but selectivity between IFNα and TNFα induction needs to be optimized
Solution Approach 1:
The patent applies local quality by designing compounds with specific structural features that target particular TLR7 recognition patterns. The differentiated substitution patterns (R1, R2, R3, m values) create localized chemical properties that preferentially engage TLR7 signaling pathways leading to IFNα production, while minimizing activation of alternative pathways that produce TNFα.
3Adaptability or versatility
If novel compounds of formula (I) are developed, then selectivity for IFNα over TNFα is achieved, but development and characterization complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the compound structure into distinct functional regions (R1, R2, R3, m positions) that can be independently optimized. This modular approach allows systematic evaluation of each substituent's contribution to IFNα selectivity, simplifying the characterization process through structure-activity relationship (SAR) analysis of individual structural elements.
Data Source
AI summary
Compounds of formula (I) and salts thereof: wherein R1 is n-C3-6alkyl; R2 is hydrogen or methyl; R3 is hydrogen or C1-6alkyl, and m is an integer having a value of 0 to 3; are inducers of human interferon. Compounds which induce human interferon may be useful in the treatment of various disorders, for example the treatment of allergic diseases and other inflammatory conditions, for example allergic rhinitis and asthma, infectious diseases and cancer, and may also be useful as vaccine adjuvants.